Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

October 18, 2016

Zykadia Better than Chemo as Second-line Treatment of Specific Lung Cancer, Trial Finds

News

Patients with non-small cell lung cancer (NSCLC) who have an ALK gene rearrangement and who were previously treated with the ALK inhibitor Xalkori (crizotinib) may strongly benefit from treatment with another ... Read more

October 13, 2016

NSCLC Patients See Significant Survival Benefit from Tecentriq, Study Finds

News

Patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on platinum-based chemotherapy benefit more from the anti-PD-L1 immunotherapy Tecentriq (atezolizumab) than from standard Taxotere (docetaxel) chemotherapy, results of a ... Read more

October 6, 2016

Alecensa Receives FDA Breakthrough Therapy Designation for First-Line Treatment of ALK-Positive NSCLC

News

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Genentech’s anaplastic lymphoma kinase (ALK) inhibitor Alecensa (alectinib) for the treatment of adults with ALK-positive non-small cell lung ... Read more

September 22, 2016

Blocking Production of Fat Molecules May Be Promising Approach to Treat Cancer

News

Blocking the synthesis of fat molecules, which are required to build plasma membranes and other cellular structures, may be a promising therapeutic approach to halt cancer’s growth, a new study suggests. ... Read more

September 15, 2016September 15, 2016

Blood-Based Test May Offer Alternative to Biopsy in Treating Advanced Lung Cancers

News

Patients with advanced non-small cell lung cancer (NSCLC) may be more effectively and safely tested for clinically relevant mutations — used to help guide treatment course — with a blood-based ... Read more